» Articles » PMID: 38243232

Multi-omics Analysis Reveals Overactive Inflammation and Dysregulated Metabolism in Severe Community-acquired Pneumonia Patients

Overview
Journal Respir Res
Specialty Pulmonary Medicine
Date 2024 Jan 19
PMID 38243232
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Severe community-acquired pneumonia (S-CAP) is a public health threat, making it essential to identify novel biomarkers and investigate the underlying mechanisms of disease severity.

Methods: Here, we profiled host responses to S-CAP through proteomics analysis of plasma samples from a cohort of S-CAP patients, non-severe (NS)-CAP patients, diseases controls (DCs), and healthy controls (HCs). Then, typical differentially expressed proteins were then validated by ELISA in an independent cohort. Metabolomics analysis was further performed on both the cohort 1 and cohort 2. Then, the proteomic and metabolomic signatures were compared between the adult and child cohorts to explore the characteristics of severe pneumonia patients.

Results: There were clear differences between CAP patients and controls, as well as substantial differences between the S-CAP and NS-CAP. Pathway analysis of changes revealed excessive inflammation, suppressed immunity, and lipid metabolic disorders in S-CAP cases. Interestingly, comparing these signatures between the adult and child cohorts confirmed that overactive inflammation and dysregulated lipid metabolism were common features of S-CAP patients, independent of age. The change proportion of glycerophospholipids, glycerolipids, and sphingolipids were obviously different in the adult and child S-CAP cases.

Conclusion: The plasma multi-omics profiling revealed that excessive inflammation, suppressed humoral immunity, and disordered metabolism are involved in S-CAP pathogenesis.

Citing Articles

Longitudinal multi-omics analysis of convalescent individuals with respiratory sequelae 6-36 months after COVID-19.

Yang H, Guan L, Xue Y, Li X, Gao L, Zhang Z BMC Med. 2025; 23(1):134.

PMID: 40038650 PMC: 11881263. DOI: 10.1186/s12916-025-03971-w.


Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infections.

Rischke S, Gurke R, Zielbauer A, Ziegler N, Hahnefeld L, Kohm M Sci Rep. 2025; 15(1):1922.

PMID: 39809876 PMC: 11733231. DOI: 10.1038/s41598-025-85229-2.


Association between 25-hydroxy vitamin D, interleukin-4, and interferon-γ levels and asthma in children with Mycoplasma pneumonia infection.

Shen T, Liu T, Kong L, Li Y Sci Rep. 2024; 14(1):28854.

PMID: 39572779 PMC: 11582317. DOI: 10.1038/s41598-024-80322-4.


Mapping Host-Microbe Omics Interactions in Severe Community-acquired Pneumonia.

Ji H, Liu G Am J Respir Cell Mol Biol. 2024; .

PMID: 39137326 PMC: 11707665. DOI: 10.1165/rcmb.2024-0346ED.


Implementation of multiomic mass spectrometry approaches for the evaluation of human health following environmental exposure.

Ferreira C, Lima Gomes P, Robison K, Cooper B, Shannahan J Mol Omics. 2024; 20(5):296-321.

PMID: 38623720 PMC: 11163948. DOI: 10.1039/d3mo00214d.

References
1.
Taz T, Ahmed K, Paul B, Al-Zahrani F, Mahmud S, Moni M . Identification of biomarkers and pathways for the SARS-CoV-2 infections that make complexities in pulmonary arterial hypertension patients. Brief Bioinform. 2021; 22(2):1451-1465. PMC: 7929374. DOI: 10.1093/bib/bbab026. View

2.
Mutlu A, Duffy J, Wang M . Lipid metabolism and lipid signals in aging and longevity. Dev Cell. 2021; 56(10):1394-1407. PMC: 8173711. DOI: 10.1016/j.devcel.2021.03.034. View

3.
Cirstea M, Walley K, Russell J, Brunham L, Genga K, Boyd J . Decreased high-density lipoprotein cholesterol level is an early prognostic marker for organ dysfunction and death in patients with suspected sepsis. J Crit Care. 2016; 38:289-294. DOI: 10.1016/j.jcrc.2016.11.041. View

4.
Huang X, Luu L, Jia N, Zhu J, Fu J, Xiao F . Multi-Platform Omics Analysis Reveals Molecular Signatures for Pathogenesis and Activity of Systemic Lupus Erythematosus. Front Immunol. 2022; 13:833699. PMC: 9063006. DOI: 10.3389/fimmu.2022.833699. View

5.
Govea-Alonso D, Beltran-Lopez J, Salazar-Gonzalez J, Vargas-Morales J, Rosales-Mendoza S . Progress and future opportunities in the development of vaccines against atherosclerosis. Expert Rev Vaccines. 2016; 16(4):337-350. DOI: 10.1080/14760584.2017.1258309. View